Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis

被引：232

作者：

Costa, Aline G. ^{[1
]}

Cusano, Natalie E. ^{[1
]}

Silva, Barbara C. ^{[1
]}

Cremers, Serge ^{[1
]}

Bilezikian, John P. ^{[1
]}

机构：

[1] Columbia Univ, Dis Unit, Div Endocrinol, Coll Phys & Surg,Dept Med, New York, NY 10032 USA

来源：

NATURE REVIEWS RHEUMATOLOGY | 2011年 / 7卷 / 08期

关键词：

BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; INHIBITOR ODANACATIB; MOLECULAR-CLONING; BREAST-CANCER; DOUBLE-BLIND; IN-VIVO; PYCNODYSOSTOSIS; COLLAGEN; GENE;

D O I：

10.1038/nrrheum.2011.77

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bone remodeling consists of two phases-bone resorption and bone formation-that are normally balanced. When bone resorption exceeds bone formation, pathologic processes, such as osteoporosis, can result. Cathepsin K is a member of the papain family of cysteine proteases that is highly expressed by activated osteoclasts. Cathepsin K readily degrades type I collagen, the major component of the organic bone matrix. With such a major role in the initial process of bone resorption, cathepsin K has become a therapeutic target in osteoporosis. The antiresorptive properties of cathepsin K inhibitors have been studied in phase I and phase II clinical trials. Phase III studies are currently underway for odanacatib, a selective cathepsin K inhibitor.

引用

页码：447 / 456

页数：10

共 95 条

[1]

Adami S, 2006, J BONE MINER RES, V21, pS24

[2] Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (Type II autosomal dominant osteopetrosis) [J].

Alatalo, SL ;

Ivaska, KK ;

Waguespack, SG ;

Econs, MJ ;

Väänänen, HK ;

Halleen, JM .

CLINICAL CHEMISTRY, 2004, 50 (05) :883-890

[3] Proteolysis of human bone collagen by cathepsin K: Characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope [J].

Atley, LM ;

Mort, JS ;

Lalumiere, M ;

Eyre, DR .

BONE, 2000, 26 (03) :241-247

[4] Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand [J].

Balkan, Wayne ;

Martinez, Ariel F. ;

Fernandez, Isabel ;

Rodriguez, Maria A. ;

Pang, Manhui ;

Troen, Bruce R. .

GENE, 2009, 446 (02) :90-98

[5] Discontinuation of Odanacatib and Other Osteoporosis Treatments: Here Today and Gone Tomorrow? [J].

Bauer, Douglas C. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (02) :239-241

[6] Craniosynostosis in Pycnodysostosis: Broadening the Spectrum of the Cranial Flat Bone Abnormalities [J].

Bertola, Debora ;

Amaral, Cassio ;

Kim, Chong ;

Albano, Lilian ;

Aguena, Meire ;

Passos-Bueno, Maria Rita .

AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2010, 152A (10) :2599-2603

[7]

Black WC, 2010, CURR TOP MED CHEM, V10, P745

[8] A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer [J].

Body, JJ ;

Facon, T ;

Coleman, RE ;

Lipton, A ;

Geurs, F ;

Fan, M ;

Holloway, D ;

Peterson, MC ;

Bekker, P .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1221-1228

[9] Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass [J].

Bone, Henry G. ;

Bolognese, Michael A. ;

Yuen, Chui Kin ;

Kendler, David L. ;

Miller, Paul D. ;

Yang, Yu-Ching ;

Grazette, Luanda ;

San Martin, Javier ;

Gallagher, J. Christopher .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04) :972-980

[10] Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density [J].

Bone, Henry G. ;

McClung, Michael R. ;

Roux, Christian ;

Recker, Robert R. ;

Eisman, John A. ;

Verbruggen, Nadia ;

Hustad, Carolyn M. ;

DaSilva, Carolyn ;

Santora, Arthur C. ;

Ince, B. Avery .

JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (05) :937-947

← 1 2 3 4 5 6 7 8 9 10 →